CD274 and lung carcinoma: Clinical studies in lung cancer have revealed that inhibiting the PD-L1/PD-1 axis results in a significantly improved clinical outcome in ~15–20% of patients with lung cancer when compared to standard of care chemotherapy [8,9,10] and thus shows promise in improving patient prognosis.